1. Pancreatic polypeptide inhibits somatostatin secretion.
- Author
-
Kim W, Fiori JL, Shin YK, Okun E, Kim JS, Rapp PR, and Egan JM
- Subjects
- Animals, Gene Expression Regulation drug effects, Hippocampus cytology, Humans, Islets of Langerhans drug effects, Islets of Langerhans metabolism, Mice, Organ Specificity, Receptors, Neuropeptide Y agonists, Receptors, Neuropeptide Y metabolism, Pancreatic Polypeptide pharmacology, Somatostatin metabolism
- Abstract
Pancreatic polypeptide (PP) is a major agonist for neuropeptide Y4 receptors (NPY4R). While NPY4R has been identified in various tissues, the cells on which it is expressed and its function in those cells has not been clearly delineated. Here we report that NPY4R is present in all somatostatin-containing cells of tissues that we tested, including pancreatic islets, duodenum, hippocampus, and hypothalamus. Its agonism by PP decreases somatostatin secretion from human islets. Mouse embryonic hippocampal (mHippo E18) cells expressed NPY4Rs and their activation by PP consistently decreased somatostatin secretion. Furthermore, central injection of PP in mice induced c-Fos immunoreactivity in somatostatin-containing cells in the hippocampus compared with PBS-injected mice. In sum, our results identify PP as a pivotal modulator of somatostatin secretion., (Published by Elsevier B.V.)
- Published
- 2014
- Full Text
- View/download PDF